Atossa Genetics (ATOS) Stock Price, News & Analysis

Company Overview

Atossa Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company has evaluated the therapy in clinical studies involving patients with breast cancer and continues to advance its development through additional research and clinical testing.

Headquartered in Seattle, Washington, Atossa conducts its development activities through clinical research and collaborations with medical institutions and investigators. The company was founded in 2009 and initially pursued products and technologies related to breast health and cancer diagnostics before focusing more heavily on therapeutic development.

Key Stats

• Today's Range: $2.08 to $2.31
• 50-Day Range: $1.90 to $2.91
• 52-Week Range: $1.70 to $14.85
• Volume: 55,533 shs
• Average Volume: 80,954 shs
• Market Capitalization: $21.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.33
• Consensus Rating: Moderate Buy

Atossa Genetics Stock Analysis - MarketRank™

Atossa Genetics scored higher than 47% of companies evaluated by MarketBeat, and ranked 571st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Atossa Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Atossa Genetics has a consensus price target of $20.33, representing about 850.2% upside from its current price of $2.14.

Amount of Analyst Coverage

Atossa Genetics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atossa Genetics are expected to grow in the coming year, from ($3.75) to ($2.78) per share.

Price to Book Value per Share Ratio

Atossa Genetics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.85% of the float of Atossa Genetics has been sold short.

Short Interest Ratio / Days to Cover

Atossa Genetics has a short interest ratio ("days to cover") of 7.59.

Change versus previous month

Short interest in Atossa Genetics has recently decreased by 22.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atossa Genetics does not currently pay a dividend.

Dividend Growth

Atossa Genetics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Atossa Genetics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

3 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atossa Genetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of Atossa Genetics is held by insiders.

Percentage Held by Institutions

12.74% of the stock of Atossa Genetics is held by institutions.

Company Calendar

• Today: 11/10/2026
• Last Earnings: 11/10/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ATOS
• CIK: 1488039
• Web: atossatherapeutics.com
• Phone: (206) 588-0256
• Fax: 206-430-1288
• Employees: 14
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Atossa Genetics: $20.33
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +850.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -102.99%
• Return on Assets: -85.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.69
• Quick Ratio: 5.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.57 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 9,980,000
• Free Float: 9,001,000
• Market Cap: $21.36 million
• Optionable: Optionable
• Beta: 1.38